Published in Cancer Cell on February 15, 2011
Tumor metastasis: molecular insights and evolving paradigms. Cell (2011) 10.34
Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors. Nature (2012) 8.13
Intra-tumour heterogeneity: a looking glass for cancer? Nat Rev Cancer (2012) 6.82
Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer. Nat Genet (2012) 5.28
Clonal competition with alternating dominance in multiple myeloma. Blood (2012) 4.39
Non-cell-autonomous driving of tumour growth supports sub-clonal heterogeneity. Nature (2014) 2.91
Tumour cell heterogeneity maintained by cooperating subclones in Wnt-driven mammary cancers. Nature (2014) 2.75
Unravelling the complexity of metastasis - molecular understanding and targeted therapies. Nat Rev Cancer (2011) 2.64
Plasticity of tumour and immune cells: a source of heterogeneity and a cause for therapy resistance? Nat Rev Cancer (2013) 1.61
RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer. Nat Commun (2015) 1.50
Metastatic colonization by circulating tumour cells. Nature (2016) 1.31
Identification of a SOX2-dependent subset of tumor- and sphere-forming glioblastoma cells with a distinct tyrosine kinase inhibitor sensitivity profile. Neuro Oncol (2011) 1.16
Mitochondrial localization and the persistent migration of epithelial cancer cells. Biophys J (2013) 1.16
Cancer: The complex seeds of metastasis. Nature (2015) 1.11
Origins, genetic landscape, and emerging therapies of small cell lung cancer. Genes Dev (2015) 1.11
Small Cell Lung Cancer: Can Recent Advances in Biology and Molecular Biology Be Translated into Improved Outcomes? J Thorac Oncol (2016) 1.03
Transdifferentiation of lung adenocarcinoma in mice with Lkb1 deficiency to squamous cell carcinoma. Nat Commun (2014) 1.02
The tumour suppressor and chromatin-remodelling factor BRG1 antagonizes Myc activity and promotes cell differentiation in human cancer. EMBO Mol Med (2012) 1.00
Paracrine signaling between tumor subclones of mouse SCLC: a critical role of ETS transcription factor Pea3 in facilitating metastasis. Genes Dev (2015) 0.99
Transcription Factor NFIB Is a Driver of Small Cell Lung Cancer Progression in Mice and Marks Metastatic Disease in Patients. Cell Rep (2016) 0.94
Small cell lung cancer: will recent progress lead to improved outcomes? Clin Cancer Res (2015) 0.94
An epigenetically distinct breast cancer cell subpopulation promotes collective invasion. J Clin Invest (2015) 0.91
Surviving at a distance: organ specific metastasis. Trends Cancer (2015) 0.90
Increased mitochondrial function downstream from KDM5A histone demethylase rescues differentiation in pRB-deficient cells. Genes Dev (2015) 0.87
The mini-driver model of polygenic cancer evolution. Nat Rev Cancer (2015) 0.87
Stemness and inducing differentiation of small cell lung cancer NCI-H446 cells. Cell Death Dis (2013) 0.87
Mesenchymal-transitioned cancer cells instigate the invasion of epithelial cancer cells through secretion of WNT3 and WNT5B. Cancer Sci (2014) 0.86
Neuroendocrine and epithelial phenotypes in small-cell lung cancer: implications for metastasis and survival in patients. Br J Cancer (2013) 0.86
Tumor cell heterogeneity in Small Cell Lung Cancer (SCLC): phenotypical and functional differences associated with Epithelial-Mesenchymal Transition (EMT) and DNA methylation changes. PLoS One (2014) 0.85
Lung cancer stem cells: Molecular features and therapeutic targets. Mol Aspects Med (2013) 0.85
Intratumoral heterogeneity: Clonal cooperation in epithelial-to-mesenchymal transition and metastasis. Cell Adh Migr (2014) 0.82
Self-folding single cell grippers. Nano Lett (2014) 0.82
Hypothermia activates adipose tissue to promote malignant lung cancer progression. PLoS One (2013) 0.81
Systems biology approaches to develop innovative strategies for lung cancer therapy. Cell Death Dis (2014) 0.81
Lineage factors and differentiation states in lung cancer progression. Oncogene (2015) 0.81
Growth suppression by MYC inhibition in small cell lung cancer cells with TP53 and RB1 inactivation. Oncotarget (2016) 0.80
Knockdown of SUMO-activating enzyme subunit 2 (SAE2) suppresses cancer malignancy and enhances chemotherapy sensitivity in small cell lung cancer. J Hematol Oncol (2015) 0.80
Disseminated cerebellar hemangioblastoma in two patients without von Hippel-Lindau disease. Surg Neurol Int (2014) 0.79
Small cell lung cancer (SCLC): no treatment advances in recent years. Transl Lung Cancer Res (2016) 0.79
Is the Canonical RAF/MEK/ERK Signaling Pathway a Therapeutic Target in SCLC? J Thorac Oncol (2016) 0.78
Identification and Targeting of Long-Term Tumor-Propagating Cells in Small Cell Lung Cancer. Cell Rep (2016) 0.78
Developmental Insights into Breast Cancer Intratumoral Heterogeneity. Trends Cancer (2015) 0.78
The role of tumor microenvironment in therapeutic resistance. Oncotarget (2016) 0.78
Plasminogen activator inhibitor-1 enhances radioresistance and aggressiveness of non-small cell lung cancer cells. Oncotarget (2016) 0.77
An orthotopic mouse model of small cell lung cancer reflects the clinical course in patients. Clin Exp Metastasis (2016) 0.77
Intracellular signals of lung cancer cells as possible therapeutic targets. Cancer Sci (2015) 0.77
Quantification of HER2 heterogeneity in breast cancer-implications for identification of sub-dominant clones for personalised treatment. Sci Rep (2016) 0.77
Novel hybrid phenotype revealed in Small Cell Lung Cancer by a transcription factor network model that can explain tumor heterogeneity. Cancer Res (2016) 0.76
EZH2 promotes progression of small cell lung cancer by suppressing the TGF-β-Smad-ASCL1 pathway. Cell Discov (2015) 0.76
Altered TGF-α/β signaling drives cooperation between breast cancer cell populations. FASEB J (2016) 0.75
miR-127 promotes EMT and stem-like traits in lung cancer through a feed-forward regulatory loop. Oncogene (2016) 0.75
MYC Drives Progression of Small Cell Lung Cancer to a Variant Neuroendocrine Subtype with Vulnerability to Aurora Kinase Inhibition. Cancer Cell (2016) 0.75
Tumor heterogeneity-induced signaling regulates SCLC metastasis. Cell Cycle (2015) 0.75
CXCR4 antagonists suppress small cell lung cancer progression. Oncotarget (2016) 0.75
Small-cell lung cancer: what we know, what we need to know and the path forward. Nat Rev Cancer (2017) 0.75
Cell state plasticity, stem cells, EMT, and the generation of intra-tumoral heterogeneity. NPJ Breast Cancer (2017) 0.75
Evidence of lateral transmission of aggressive features between different types of breast cancer cells. Int J Oncol (2017) 0.75
Prognostically useful gene-expression profiles in acute myeloid leukemia. N Engl J Med (2004) 11.61
A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome-wide classification study. Lancet Oncol (2009) 5.22
Suppression of anoikis and induction of metastasis by the neurotrophic receptor TrkB. Nature (2004) 4.53
Somatic inactivation of E-cadherin and p53 in mice leads to metastatic lobular mammary carcinoma through induction of anoikis resistance and angiogenesis. Cancer Cell (2006) 4.15
The structure-specific endonuclease Ercc1-Xpf is required to resolve DNA interstrand cross-link-induced double-strand breaks. Mol Cell Biol (2004) 3.94
The European dimension for the mouse genome mutagenesis program. Nat Genet (2004) 3.84
High-throughput retroviral tagging to identify components of specific signaling pathways in cancer. Nat Genet (2002) 3.81
Somatic loss of BRCA1 and p53 in mice induces mammary tumors with features of human BRCA1-mutated basal-like breast cancer. Proc Natl Acad Sci U S A (2007) 3.58
Duplication of the MYB oncogene in T cell acute lymphoblastic leukemia. Nat Genet (2007) 3.48
Monosomal karyotype in acute myeloid leukemia: a better indicator of poor prognosis than a complex karyotype. J Clin Oncol (2008) 3.47
The structure-specific endonuclease Mus81 contributes to replication restart by generating double-strand DNA breaks. Nat Struct Mol Biol (2007) 3.38
Induction of small cell lung cancer by somatic inactivation of both Trp53 and Rb1 in a conditional mouse model. Cancer Cell (2003) 3.31
p15Ink4b is a critical tumour suppressor in the absence of p16Ink4a. Nature (2007) 3.26
Large-scale mutagenesis in p19(ARF)- and p53-deficient mice identifies cancer genes and their collaborative networks. Cell (2008) 3.25
Prediction of molecular subtypes in acute myeloid leukemia based on gene expression profiling. Haematologica (2008) 3.06
Integrated transcript and genome analyses reveal NKX2-1 and MEF2C as potential oncogenes in T cell acute lymphoblastic leukemia. Cancer Cell (2011) 2.89
High EVI1 levels predict adverse outcome in acute myeloid leukemia: prevalence of EVI1 overexpression and chromosome 3q26 abnormalities underestimated. Blood (2008) 2.86
Cell of origin of small cell lung cancer: inactivation of Trp53 and Rb1 in distinct cell types of adult mouse lung. Cancer Cell (2011) 2.63
Mouse models for human lung cancer. Genes Dev (2005) 2.59
Novel prognostic subgroups in childhood 11q23/MLL-rearranged acute myeloid leukemia: results of an international retrospective study. Blood (2009) 2.57
Conditional mouse models of sporadic cancer. Nat Rev Cancer (2002) 2.47
Gene expression profiling for molecular classification of multiple myeloma in newly diagnosed patients. Blood (2010) 2.42
Pim-1 regulates cardiomyocyte survival downstream of Akt. Nat Med (2007) 2.39
Mice deficient for all PIM kinases display reduced body size and impaired responses to hematopoietic growth factors. Mol Cell Biol (2004) 2.31
Selective inhibition of BRCA2-deficient mammary tumor cell growth by AZD2281 and cisplatin. Clin Cancer Res (2008) 2.27
For better or for worse: the role of Pim oncogenes in tumorigenesis. Nat Rev Cancer (2010) 2.26
Targeted biallelic inactivation of Pten in the mouse prostate leads to prostate cancer accompanied by increased epithelial cell proliferation but not by reduced apoptosis. Cancer Res (2005) 2.19
Chromatin position effects assayed by thousands of reporters integrated in parallel. Cell (2013) 2.16
Toxicity of ligand-dependent Cre recombinases and generation of a conditional Cre deleter mouse allowing mosaic recombination in peripheral tissues. Physiol Genomics (2007) 2.15
Expression analyses identify MLL as a prominent target of 11q23 amplification and support an etiologic role for MLL gain of function in myeloid malignancies. Blood (2003) 2.13
Retroviral insertional mutagenesis: tagging cancer pathways. Adv Cancer Res (2003) 2.07
High-throughput insertional mutagenesis screens in mice to identify oncogenic networks. Nat Rev Cancer (2009) 2.06
Insertional mutagenesis identifies multiple networks of cooperating genes driving intestinal tumorigenesis. Nat Genet (2011) 2.02
High EVI1 expression predicts poor survival in acute myeloid leukemia: a study of 319 de novo AML patients. Blood (2002) 2.01
The recurrent SET-NUP214 fusion as a new HOXA activation mechanism in pediatric T-cell acute lymphoblastic leukemia. Blood (2008) 1.95
A high-throughput splinkerette-PCR method for the isolation and sequencing of retroviral insertion sites. Nat Protoc (2009) 1.95
ERCC1-XPF endonuclease facilitates DNA double-strand break repair. Mol Cell Biol (2008) 1.88
Identification of oncogenes collaborating with p27Kip1 loss by insertional mutagenesis and high-throughput insertion site analysis. Proc Natl Acad Sci U S A (2002) 1.85
The outcome of molecular-cytogenetic subgroups in pediatric T-cell acute lymphoblastic leukemia: a retrospective study of patients treated according to DCOG or COALL protocols. Haematologica (2006) 1.83
LAF4, an AF4-related gene, is fused to MLL in infant acute lymphoblastic leukemia. Genes Chromosomes Cancer (2002) 1.72
Evaluation of gene expression signatures predictive of cytogenetic and molecular subtypes of pediatric acute myeloid leukemia. Haematologica (2010) 1.71
The comparative pathology of genetically engineered mouse models for neuroendocrine carcinomas of the lung. J Thorac Oncol (2015) 1.68
Unique and overlapping functions of pRb and p107 in the control of proliferation and differentiation in epidermis. Development (2004) 1.65
PTEN is essential for cell migration but not for fate determination and tumourigenesis in the cerebellum. Development (2002) 1.64
NUP98/NSD1 characterizes a novel poor prognostic group in acute myeloid leukemia with a distinct HOX gene expression pattern. Blood (2011) 1.64
The cryptic chromosomal deletion del(11)(p12p13) as a new activation mechanism of LMO2 in pediatric T-cell acute lymphoblastic leukemia. Blood (2006) 1.63
NCAM-induced focal adhesion assembly: a functional switch upon loss of E-cadherin. EMBO J (2008) 1.62
Cell of origin of lung cancer. Mol Oncol (2010) 1.54
Oncogene addiction: sometimes a temporary slavery. Cancer Cell (2004) 1.54
Leukemia-associated NF1 inactivation in patients with pediatric T-ALL and AML lacking evidence for neurofibromatosis. Blood (2008) 1.51
Molecular-genetic insights in paediatric T-cell acute lymphoblastic leukaemia. Br J Haematol (2008) 1.50
Immune response in lung cancer mouse model mimics human anti-Hu reactivity. J Neuroimmunol (2009) 1.47
Clinical, molecular, and prognostic significance of WHO type inv(3)(q21q26.2)/t(3;3)(q21;q26.2) and various other 3q abnormalities in acute myeloid leukemia. J Clin Oncol (2010) 1.46
Noninvasive imaging of spontaneous retinoblastoma pathway-dependent tumors in mice. Cancer Res (2002) 1.46
Knockout mouse models to study Wnt signal transduction. Trends Genet (2006) 1.46
Increased genomic instability is not a prerequisite for shortened lifespan in DNA repair deficient mice. Mutat Res (2006) 1.43
Genomic and expression profiling of human spermatocytic seminomas: primary spermatocyte as tumorigenic precursor and DMRT1 as candidate chromosome 9 gene. Cancer Res (2006) 1.41
Sensitivity to L-asparaginase is not associated with expression levels of asparagine synthetase in t(12;21)+ pediatric ALL. Blood (2002) 1.36
Mouse models of prostate adenocarcinoma with the capacity to monitor spontaneous carcinogenesis by bioluminescence or fluorescence. Cancer Res (2007) 1.33
Multiple cells-of-origin of mutant K-Ras-induced mouse lung adenocarcinoma. Proc Natl Acad Sci U S A (2014) 1.30
Comparative analysis of the value of allogeneic hematopoietic stem-cell transplantation in acute myeloid leukemia with monosomal karyotype versus other cytogenetic risk categories. J Clin Oncol (2012) 1.30
Identification of NUP98 abnormalities in acute leukemia: JARID1A (12p13) as a new partner gene. Genes Chromosomes Cancer (2006) 1.27
Loss of p27(Kip1) but not p21(Cip1) decreases survival and synergizes with MYC in murine lymphomagenesis. EMBO J (2002) 1.26
Prognostic significance of additional cytogenetic aberrations in 733 de novo pediatric 11q23/MLL-rearranged AML patients: results of an international study. Blood (2011) 1.25
Mutation of the mouse Rad17 gene leads to embryonic lethality and reveals a role in DNA damage-dependent recombination. EMBO J (2004) 1.22
Risk stratification of intermediate-risk acute myeloid leukemia: integrative analysis of a multitude of gene mutation and gene expression markers. Blood (2011) 1.21
Activating FLT3 mutations in CD4+/CD8- pediatric T-cell acute lymphoblastic leukemias. Blood (2005) 1.21
Targeting FLT3 in primary MLL-gene-rearranged infant acute lymphoblastic leukemia. Blood (2005) 1.20
The generation of a conditional reporter that enables bioluminescence imaging of Cre/loxP-dependent tumorigenesis in mice. Cancer Res (2003) 1.19
Mouse models for lung cancer. Mol Oncol (2013) 1.18
Rapid target gene validation in complex cancer mouse models using re-derived embryonic stem cells. EMBO Mol Med (2014) 1.17
Tumor formation in mice with somatic inactivation of the retinoblastoma gene in interphotoreceptor retinol binding protein-expressing cells. Oncogene (2002) 1.16
Concurrent loss of chromosome arm 1p and chromosome 3 predicts a decreased disease-free survival in uveal melanoma patients. Invest Ophthalmol Vis Sci (2005) 1.14
A conditional mouse model for malignant mesothelioma. Cancer Cell (2008) 1.14
Integrative analysis of type-I and type-II aberrations underscores the genetic heterogeneity of pediatric acute myeloid leukemia. Haematologica (2011) 1.14
DCC expression by neurons regulates synaptic plasticity in the adult brain. Cell Rep (2013) 1.13
Clinical and cytogenetic analyses in uveal melanoma. Invest Ophthalmol Vis Sci (2006) 1.11
Asparagine synthetase expression is linked with L-asparaginase resistance in TEL-AML1-negative but not TEL-AML1-positive pediatric acute lymphoblastic leukemia. Blood (2005) 1.11
Further characterization of the first seminoma cell line TCam-2. Genes Chromosomes Cancer (2008) 1.09
Deleted in colorectal carcinoma suppresses metastasis in p53-deficient mammary tumours. Nature (2012) 1.08
Decreased PARP and procaspase-2 protein levels are associated with cellular drug resistance in childhood acute lymphoblastic leukemia. Blood (2005) 1.07
Rb and p107 are required for normal cerebellar development and granule cell survival but not for Purkinje cell persistence. Development (2003) 1.07
Complex karyotype newly defined: the strongest prognostic factor in advanced childhood myelodysplastic syndrome. Blood (2010) 1.05